GlassScriptPhysician profile
Umang Patel
NPI 1922390285
$21,223.91
in general payments reported to CMS, 2019-2025
18 companies · $187 in 2025
The $187 reported for 2025 was more than what 75% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $296 · 2021: $5,380 · 2022: $4,867 · 2023: $1,523 · 2024: $8,540 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,810 · Travel and Lodging: $1,534 · Food and Beverage: $1,036 · Consulting Fee: $870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,810.00 |
| Travel and Lodging | $1,533.64 |
| Food and Beverage | $1,035.88 |
| Consulting Fee | $870.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $20,053.61 | 2021-2025 | Veklury |
| Janssen Pharmaceuticals, INC | $336.59 | 2019-2023 | Xarelto |
| Pfizer INC. | $174.60 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $106.80 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.25 | 2019-2021 | |
| Abbott Laboratories | $83.60 | 2019-2025 | Jot Dx, Tacticath Ablation Catheter, Sensor Enabled |
| Mylan Specialty L.P. | $73.39 | 2019-2022 | |
| Abbvie INC. | $67.19 | 2021-2024 | |
| Novo Nordisk INC | $37.22 | 2021-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $31.10 | 2019 | |
| Cook Medical LLC | $27.88 | 2020 | |
| Aimmune Therapeutics, INC. | $24.21 | 2023 | |
| Philips North America LLC | $23.67 | 2025 | Vest Therapy Und |
| Smith+Nephew, INC. | $22.42 | 2022 | |
| Vyera Pharmaceuticals, LLC | $18.14 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $17.08 | 2019 | |
| Shire North American Group INC | $15.00 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umang Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.